Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039

Reuters

06-06

<a href="https://laohu8.com/S/TBPH">Theravance Biopharma Inc.</a> and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039

Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541855726"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541855726\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541855726?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-06 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541855726","market":"nz","top_or_hot":-1,"title":"Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma Inc.</a> and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTheravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-06 18:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TBPH\">Theravance Biopharma Inc.</a> and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TBPH","symbol_name":"Theravance Biopharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250606:nNDL3Ffm98:1","article_id":"2541855726","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541855726","pubTimestamp":1749204227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI  inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TBPH":"Theravance Biopharma Inc.","BK4007":"制药"},"translate_title":"Theravance Biopharma Inc.和Mylan就YUPELRI®专利纠纷与Eugia达成和解，允许仿制药于2039年上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TBPH":0.9},"content_text":"Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039\n    \n\n        Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-056996), on June 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}